KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Emergent BioSolutions (EBS) over the last 17 years, with Q3 2025 value amounting to -$21.6 million.

  • Emergent BioSolutions' Net Cash Flow fell 12529.27% to -$21.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $92.7 million, marking a year-over-year increase of 3223.97%. This contributed to the annual value of -$6.1 million for FY2024, which is 9884.84% up from last year.
  • Per Emergent BioSolutions' latest filing, its Net Cash Flow stood at -$21.6 million for Q3 2025, which was down 12529.27% from $117.2 million recorded in Q2 2025.
  • Emergent BioSolutions' 5-year Net Cash Flow high stood at $400.5 million for Q4 2022, and its period low was -$343.6 million during Q2 2023.
  • For the 5-year period, Emergent BioSolutions' Net Cash Flow averaged around -$19.5 million, with its median value being -$32.7 million (2024).
  • As far as peak fluctuations go, Emergent BioSolutions' Net Cash Flow tumbled by 63823.53% in 2021, and later skyrocketed by 459473.68% in 2024.
  • Emergent BioSolutions' Net Cash Flow (Quarter) stood at $172.3 million in 2021, then soared by 132.44% to $400.5 million in 2022, then crashed by 93.66% to $25.4 million in 2023, then plummeted by 300.0% to -$50.8 million in 2024, then skyrocketed by 57.48% to -$21.6 million in 2025.
  • Its Net Cash Flow was -$21.6 million in Q3 2025, compared to $117.2 million in Q2 2025 and $47.9 million in Q1 2025.